COMMUNIQUÉS West-GlobeNewswire

Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)
01/03/2018
EXTON, Pa. and CAMBRIDGE, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA ), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients [...]
Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2017 Results
01/03/2018
NASHVILLE, Tenn., March 01, 2018 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ: SGRY ) ("Surgery Partners" or the "Company"), a leading provider of surgical services, today announced results for the fourth quarter [...]
Revive Therapeutics and Ehave Enter Into Patient Research Data Collaboration Agreement for Medical Cannabis Liver Disease Program
01/03/2018
TORONTO, March 01, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (" Revive ") (TSX-V: RVV ) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel cannabinoid solutions, and [...]
Chimerix Announces Fourth Quarter and Full Year 2017 Financial Results
01/03/2018
- AdVance Data to be Presented at EBMT Annual Meeting - - Oral and IV BCV Programs Remain on Track - - Conference Call at 8:30 a.m. ET Today - DURHAM, N.C., March 01, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX ), a [...]
G1 Therapeutics to Present at Investor Conferences in March 2018
01/03/2018
RESEARCH TRIANGLE PARK, N.C., March 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D., will [...]
Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer
01/03/2018
SAN FRANCISCO, March 01, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN ), a science-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track [...]
MPX Reports Q3 Fiscal 2018 Results
01/03/2018
TORONTO, March 01, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (the “ Corporation ” or “ MPX ”) (CSE:MPX) (OTCQB:MPXEF) reports financial results for its third quarter period ended December 31, 2017. (CDN$) 3 [...]
Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Remains on Track for Commercial Launch by First Quarter 2019
01/03/2018
Completed submission of NDAs for oral and intravenous omadacycline for the treatment of pneumonia and skin infections Expanded medical affairs and payer account management teams in readiness for discussions with [...]
Cannabis Wheaton Income Corp. and Sundial Sign Definitive Agreement for $7,000,000 in Debt Financing
01/03/2018
VANCOUVER, British Columbia, March 01, 2018 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (TSX-V: CBW ) ( "Cannabis Wheaton" or the " Company ") is pleased to announce that it has entered into a definitive agreement [...]
News Release: Proposed combination between Essilor and Luxottica approved without conditions by the European Commission
01/03/2018
Proposed combination between Essilor and Luxottica approved without conditions by the European Commission PDF Version of the news release Charenton-le-Pont, France and Milan, Italy ( March 1, 2018 ) - Essilor (Euronext [...]
Communiqué : La Commission Européenne autorise sans condition le projet de rapprochement entre Essilor et Luxottica
01/03/2018
La Commission Européenne autorise sans condition le projet de rapprochement entre Essilor et Luxottica Version PDF du communiqué Charenton-le-Pont, France et Milan, Italie (le 1 er mars 2018) - Essilor (Euronext Paris [...]
Loxo Oncology Reports Fourth Quarter and Year-End 2017 Financial Results
01/03/2018
– Larotrectinib Rolling NDA Submission on Track for Completion in March – – LOXO-292 Phase 1 Clinical Data Update Expected in First Half 2018 – STAMFORD, Conn., March 01, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. ( [...]
Edge Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
01/03/2018
Interim Analysis from EG-1962 Phase 3 NEWTON 2 Study in Aneurysmal Subarachnoid Hemorrhage Expected by the End of April 2018 Full Top-Line Data from NEWTON 2 Study Expected in Late 2018 BERKELEY HEIGHTS, N.J., March 01 [...]
Wright Medical Group N.V. to Present at Barclays Global Healthcare Conference
01/03/2018
AMSTERDAM, The Netherlands, March 01, 2018 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ: WMGI ) announced today that it will present at Barclays Global Healthcare Conference on Thursday, March 15, 2018, at the [...]
PotNetwork Holding Inc. Generates Over $3,000,000 in Sales Over First 45 days of 2018
01/03/2018
FT LAUDERDALE, Fla., March 01, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- PotNetwork Holding, Inc. (OTC Pink:POTN) (“Company”) announced today that its wholly owned subsidiary, Diamond CBD, Inc., just one and a half [...]
Shire plc : Total voting rights
01/03/2018
Total Voting Rights March 1, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority's (the "FCA") Disclosure Guidance and Transparency Rules, notifies the [...]
BIOPHYTIS updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami
01/03/2018
Additional data confirm the relevance of the protocol and the compound in the clinical study SARA-INT phase 2B PARIS, March 01, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS) , a biotechnology company [...]
iCAD Granted CE Mark Approval in Europe for PowerLook Tomo Detection 2.0 Artificial Intelligence Solution
01/03/2018
Company’s Innovative Breast Cancer Detection Product is Compatible with Hologic, GE and Siemens Digital Breast Tomosynthesis Systems Significantly Expanding iCAD’s Global Market Opportunity VIENNA, Austria, March 01, [...]
Basilea names Adesh Kaul as new member of its Management Committee
01/03/2018
Basel, Switzerland, March 01, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Adesh Kaul will join Basilea's Management Committee as Chief Corporate Development Officer effective March 01, 2018. He [...]

Pages